22 research outputs found
The determinants of the global digital divide : a cross-country analysis of computer and internet penetration
Renormalization group flows and continual Lie algebras
We study the renormalization group flows of two-dimensional metrics in sigma
models and demonstrate that they provide a continual analogue of the Toda field
equations based on the infinite dimensional algebra G(d/dt;1). The resulting
Toda field equation is a non-linear generalization of the heat equation, which
is integrable in target space and shares the same dissipative properties in
time. We provide the general solution of the renormalization group flows in
terms of free fields, via Backlund transformations, and present some simple
examples that illustrate the validity of their formal power series expansion in
terms of algebraic data. We study in detail the sausage model that arises as
geometric deformation of the O(3) sigma model, and give a new interpretation to
its ultra-violet limit by gluing together two copies of Witten's
two-dimensional black hole in the asymptotic region. We also provide some new
solutions that describe the renormalization group flow of negatively curved
spaces in different patches, which look like a cane in the infra-red region.
Finally, we revisit the transition of a flat cone C/Z_n to the plane, as
another special solution, and note that tachyon condensation in closed string
theory exhibits a hidden relation to the infinite dimensional algebra G(d/dt;1)
in the regime of gravity. Its exponential growth holds the key for the
construction of conserved currents and their systematic interpretation in
string theory, but they still remain unknown.Comment: latex, 73pp including 14 eps fig
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
BackgroundA safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials.MethodsThis analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5âĂâ1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1â-ârelative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674.FindingsBetween April 23 and Nov 4, 2020, 23â848 participants were enrolled and 11â636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0â75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4â97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8â80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74â341 person-months of safety follow-up (median 3·4 months, IQR 1·3â4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation.InterpretationChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials.FundingUK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede DâOr, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca
A Decomposition of Gender Differences on the Poverty among the Urban Working Households in Korea
A conversation with 590 Nascent Entrepreneurs
Panel study of entrepreneurial dynamics, Entry, Business development, Business partnership, Family business, Business credit, L26, M13,